Residual inflammation in the cerebrospinal fluid after short- and long-term natalizumab treatment in relapsing-remitting multiple sclerosis
Background and objectivesNatalizumab (NTZ) is a high-efficacy therapy for relapsing-remitting multiple sclerosis (RRMS) that blocks peripheral immune cell migration into the central nervous system. While short-term NTZ treatment reduces cerebrospinal f…